Real-world evidence and clinical studies for medical devices under the MDR

Hospitals and registries document every day what your product achieves in real use. We unlock these data and turn them into studies that your Notified Body recognises, that convince physicians and that carry through to the guidelines.

When data are missing, things get expensive quickly.

The Notified Body wants to see more. Recertification under the MDR runs until the end of 2027 or 2028, or a request with a deadline arrives. The gap cannot be closed with the old documentation.

Off-label use: your product has long been used differently. Physicians use it in children or in indications that are not in the instructions for use and the intended purpose. Before anything happens, you need data for an extension of indication or a clear exclusion.

The health insurer wants the benefit proven. For reimbursement, what counts is data that show the benefit per case. Without it, your product remains a self-pay matter.

You lack sites for the first data. The product is new, and no hospital has documented it in a structured way so far. Then it starts with 2 or 3 sites that take part.

Data from everyday clinical practice, covering all patients.

Real-World Evidence comes from data that is generated in routine care anyway: in hospital systems, patient records and registries. In an orthopaedic registry, for example, every implant has a record of how the operation went and how the patient is doing years later.

A randomised study is expensive, ends after a fixed period and often includes only a narrow slice of patients. Routine data, by contrast, shows long-term outcomes over 3 to 5 years and all patients, as they actually present in hospital. You can analyse subgroups specifically, such as children or patients with diabetes. And the MDR recognises such data as clinical data.

Randomised studySchematic
CostExpensive
PatientsOften only a narrow slice
Duration and long-term follow-upEnds after a fixed period
SubgroupsOften not included
Real-World EvidenceSchematic
CostThe data is generated in routine care anyway
PatientsAll of them, as they actually present in hospital
Duration and long-term follow-upThe data often already exists, with outcomes over 3 to 5 years
SubgroupsCan be analysed specifically, such as children or patients with diabetes

From study idea to analysis.

01Klinikdaten02Studien03Auswertung04Klin. Bewertung05PubMed

Level 1 of 5Hospital data

  1. 01
    Evidence strategy

    We establish which data your product needs by the next deadline, and in what order.

    Level 1 · Hospital data
  2. 02
    Retrospective studies

    Analysis of existing routine data from one or more sites, often the fastest route to robust evidence.

    Level 2 · Studies
  3. 03
    Registry analyses

    Long-term data from existing registries, cleanly analysed for your question.

    Level 3 · Analysis
  4. 04
    PMCF studies

    Planning, conduct and analysis, including study protocol and ethics application. The data flows straight into your reports.

    Level 4 · Clinical evaluation

Sites and key opinion leaders who take part.

Studies rarely fail because of the idea. They fail because hospitals and physicians simply cannot manage them on top of their clinical duties and patient care. That is exactly where we help. I bring the sites: research-minded, motivated physicians in Germany and abroad who do research, publish and like to take part in studies. These opinion leaders often become the voices that later sit on guideline committees.

I follow up with your users, travel to the sites and make sure the participating physicians publish as co-authors. That is often the reason they take part. If you wish, we build and look after a network of key opinion leaders of your own.

DACH Türkiye Colombia

Sites from our network, selection

So that the hospital is allowed to release the data.

The data often exists, and still nobody can get to it. The hospital administration hesitates, and data protection is unresolved. We prepare the ethics application, data protection, contracts and data processing agreement so that the hospital is legally covered and can approve. We go that route together with the physician who wants the study.

A hospital's data protection officer hands Dr. Peter Recknagel the signed contract, with the clinical director sitting beside her

114 patients for an indication extension.

A wound therapy was used in patients with a left ventricular assist device, outside its original approval. The Notified Body required evidence under the MDR. We designed and carried out a retrospective study of 114 patients, supplemented by bench tests. The Notified Body received all the evidence it had asked for.

Read the full case study
“The data we obtained gives us the confidence and clarity we need to use our technology in the demanding LVAD setting.”
COO, wound therapy manufacturer

When do you have to start on evidence at the latest?

Answer 18 short questions about your product. You then receive your Evidence Plan as a PDF: which building blocks must be ready by your next deadline, when you have to start at the latest, and what budget to expect.

Create your Evidence Plan Takes 4 minutes, is confidential and free of charge.
Example of the Evidence Plan result: deadline, latest start, budget range and timeline of the building blocks

This is what your result looks like (example)

Questions about Real-World Evidence.

What manufacturers most often want to know before a study.

Dr. Peter Recknagel
Your question is not listed?Write to me directly.
View all questions

Yes, the MDR permits data from routine care as clinical data, for PMCF for example. What matters is that the study answers exactly the questions your Notified Body asks. We clarify that before the start.

For most questions after approval, no. Registries, routine data or a structured analysis of existing cases are often enough. In the evidence call we tell you honestly what is needed and what you can save yourself.

No, we deliberately do not. We deliver the data and the evidence that go into these reports, prepared so that your regulatory team can take them over directly.

A retrospective analysis of existing data can often be done in a few months. A new study has to enrol patients first, and that takes as long as it takes. In the plan you can see from the start what is realistic by your deadline.

What does your Notified Body still need?

In the evidence call, we look at your deadline and your data in 30 minutes. Afterwards you know which study you are missing next.